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ABSTRACT
Background: The database of the German programme
for quality in healthcare including data of every
hospitalised patient with community-acquired pneumonia
(CAP) during a 2-year period (n=388 406 patients in
2005 and 2006) was analysed.
Methods: End points of the analysis were: (1) incidence;
(2) outcome; (3) performance of the CRB-65 (C, mental
confusion; R, respiratory rate >30/min; B, systolic blood
pressure ,90 mm Hg or diastolic blood pressure
(60 mm Hg; 65, age >65 years) score in predicting
death; and (4) lack of ventilatory support as a possible
indicator of treatment restrictions. The CRB-65 score was
calculated, resulting in three risk classes (RCs).
Results: The incidence of hospitalised CAP was 2.75 and
2.96 per 1000 inhabitants/year in 2005 and 2006,
respectively, higher for males (3.21 vs 2.52), and strongly
age related, with an incidence of 7.65 per 1000
inhabitants/year in patients aged >60 years over 2 years.
Mortality (13.72% and 14.44%) was higher than reported
in previous studies. The CRB-65 RCs accurately predicted
death in a three-class pattern (mortality 2.40% in CRB-65
RC 1, 13.43% in CRB-65 RC 2 and 34.39% in CRB-65 RC
3). The first days after admission were consistently
associated with the highest risk of death throughout all
risk classes. Only a minority of patients who died had
received mechanical ventilation during hospitalisation
(15.74%).
Conclusions: Hospitalised CAP basically is a condition of
the elderly associated with a higher mortality than
previously reported. It bears a considerable risk of early
mortality, even in low risk patients. CRB-65 is a simple
and powerful tool for the assessment of CAP severity.
Hospitalised CAP is a frequent terminal event in chronic
debilitated patients, and a limitation of treatment
escalation is frequently applied.
In the last two decades, considerable progress has
been made in the investigation of community-
acquired pneumonia (CAP), for example in the
understanding of severity assessment, underlying
pathogen patterns and the importance of rapid
initiation of appropriate empiric antimicrobial
treatment. These are reflected in current author-
itative guidelines for the management of adult CAP
from the USA and Europe.
1–4 Nevertheless, only
few widely representative data are available reflect-
ing the clinical presentation and outcome of
patients with CAP in real life, and only few studies
are based on large databases derived from hospital
chart records.
5–7
Since 2005, CAP was included in the nationwide
mandatory perpetual performance measurement
programme in Germany. The National Institute for
Quality in Healthcare (BQS) is responsible for
inpatient quality assurance in the German health-
care system on behalf of the Federal Joint
Committee (Gemeinsamer Bundesausschuss) and
the Ministry of Health. BQS together with
national specialty groups develops mandatory
quality assurance programmes covered by the
German Social Code, and collects and analyses
data sets of all German hospitals (.2000). The
CAP performance programme obligates all hospi-
tals in Germany to document all in-hospital
patients with CAP on a predefined quality report
sheet.
89 After 2 years, the database from this
performance measurement programme offers a
unique opportunity to report on the results of all
adult patients (>18 years) in Germany treated in
hospital with CAP in particular regarding epide-
miology, attitudes of management and outcomes.
METHODS
Database
The data items required for the nationwide perfor-
mance measurement programme were defined by
the specialty group on CAP together with the BQS.
A case of CAP was identified by encoding pneumo-
nia without severe immunosuppression (HIV infec-
tion, solid organ or bone marrow/stem cell
transplants, severe neutropenia) as the principal
diagnosis of hospital admission. The underlying
International Classification of Diseases (ICD-10-
Germanmodification(GM))codesusedforinclusion
and exclusion of cases are given in Appendix 1
(available online). These codes clearly exclude acute
bronchitis and exacerbations of chronic obstructive
pulmonary disease (COPD). Patients transferred
from another hospital had to have CAP as the initial
admission diagnosis to be included. Rehabilitation
facilities in Germany are not hospitals, and pneu-
monia acquired in these facilities was therefore
considered to be community acquired. Malignancies
were not excluded because they do not represent
severe immunosuppression per se, even during
treatment, unless there is severe neutropenia, which
in turn represents an exclusion criterion. Aspiration
pneumonia was included since it is considered as a
main cause of CAP.
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(from home, nursing home, another hospital or rehabilitation
facilities), age and sex, comorbidities according to the ICD-10-GM
(optional), clinical condition (chronically bedridden defined as
definite inability to undergo mobilisation prior to admission),
respiratory rate, systolic and diastolic blood pressure, presence of
acute pneumonia-related mental confusion at admission, the use
of ventilatory support (non-invasive or invasive), the presence of
stability criteria at discharge (including respiratory rate, systolic
and diastolic blood pressure, and mental state) and outcome
(survival or death). These data were assessed electronically.
The items of the CRB-65 (C, mental confusion; R, respiratory
rate >30/min; B, systolic blood pressure ,90 mm Hg or
diastolic blood pressure (60 mm Hg; 65, age >65 years) score
were included in the raw data. Three risk classes were calculated
(modified according to Lim et al
10) as follows: risk class (RC) 1
(CRB-65=0 points); RC 2 (CRB-65=1 or 2 points); RC 3
(CRB-65=3 or 4 points or mechanical ventilation at admission,
since no reliable assessment of respiratory rate is realistic in
these latter patients).
Additional data exclusively retrieved for purposes of the
nationwide performance measurement programme were not
included in this analysis. No data were available on pathogen
patterns and choices of antimicrobial treatment.
Statistics
Categorial variables were compared using the x
2 test and giving
the relative risks (RRs) for testing for differences across the two
observation years. The significance level was chosen to be 5%.
Baseline population figures for the calculation of the incidence of
pneumonia originated from the Statististisches Bundesamt.
11 The
incidence was calculated by dividing the number of new cases per
year by the number of persons at risk per year, illustrated as
number per 1000 inhabitants (aged >18 years) and year.
RESULTS
Database
During 2005 and 2006, 1310 of 1435 (91.3%) and 1377 of 1433
hospitals (96.1%), respectively, participated in the performance
measurement programme and delivered complete data sets.
Overall, 388 406 (2005, 186 691; 2006, 201 715) inpatient data
records of patients with CAP were retrieved and analysed.
Incidence of hospitalised CAP
In 2005 and 2006, the number of inhabitants in Germany was
82 437 995 and 82 314 906, respectively, including 67 880 591
inhabitants in 2005 and 68 072 756 in 2006 aged >18 years
(population at risk).
11 Thus, the incidence of hospitalised CAP
was 2.75 and 2.96 per 1000 inhabitants (>18 years) and year in
2005 and 2006, respectively.
The incidence of hospitalised CAP was strongly age depen-
dent and increased with every decade (fig 1). The mean
incidence in persons >60 years was 7.65 per 1000 inhabitants
and year over 2 years.
The mean incidence for males was 3.21 per 1000 inhabitants
per year as compared with 2.52 for females (fig 2)
Patient characteristics
Age and sex
In both years, the age distribution was remarkably similar, with
a median of 76 years (interquartile range (IQR)=20 and 19
years in 2005 and 2006, respectively; mean age=71.94 and
72.09 years, SD=16.86 and 17.00). The large majority of
patients were aged >60 years, accounting for 81.00% of
patients. The single largest age decade including 28.64% of
patients was 80–89 years old (table 1).
There was a preponderance of male patients in both years
(211 579 (54.47%) male vs 176 827 (45.53%) female). The raw
number of male patients exceeded the number of female
patients until the seventh decade (70–79); thereafter more
female than male patients were documented (fig 3).
Admission to hospital
A total of 86 387 patients were admitted from nursing homes
and 16 158 from other hospitals or rehabilitation facilities.
Comorbidities and clinical condition
Patient comorbidity according to ICD-10-GM is given in table 2.
The most frequent comorbidity was cardiac comorbidity
(19.2%), followed by central nervous system disorders
Figure 1 Distribution of the incidence of
hospitalised community-acquired
pneumonia per 1000 inhabitants and year
according to age classes. Incidences in
2005, 2006 and both are shown. The
indicated incidence numbers refer to the
mean incidence of an age class.
Respiratory infection
Thorax 2009;64:1062–1069. doi:10.1136/thx.2008.109785 1063Figure 2 Distribution of incidence of
hospitalised community-acquired
pneumonia per 1000 inhabitants and year
according to age classes. Incidences for
sex (overall 2005 and 2006) compared
with overall incidence are given. The
indicated incidence numbers refer to the
mean incidence of an age class.
Table 1 Age distribution
Age class (years) 2005, n (%) 2006, n (%) Total, n (%)
18–19 674 (0.36) 626 (0.31) 1300 (0.33)
20–29 4321 (2.32) 4329 (2.15) 8650 (2.23)
30–39 7290 (3.91) 7071 (3.51) 14 361 (3.70)
40–49 10 213 (5.47) 10 712 (5.31) 20 925 (5.39)
50–59 13 448 (7.21) 15 094 (7.48) 28 542 (7.35)
60–69 28 380 (15.21) 30 569 (15.15) 58 949 (15.18)
70–79 48 904 (26.20) 53 498 (26.52) 102 402 (26.37)
80–89 52 258 (28.00) 58 965 (29.23) 111 223 (28.64)
>90 21 157 (11.34) 20 849 (10.34) 42 006 (10.82)
Total patients with valid data 186 645 201 713 388 358
Forty-eight cases of the total sample had no valid age data.
Figure 3 Age and sex distribution of
patients hospitalised with community-
acquired pneumonia (total population in
2005 and 2006).
Respiratory infection
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and diabetes mellitus (11.9%).
Overall, 26.07% (101 249/388 406) patients were classified as
chronically bedridden.
Pneumonia severity at admission
Of the whole CAP population, 16.55% of patients belonged to
CRB-65 RC 1, 71.55% to CRB-65 RC 2 and 11.91% to CRB-65
RC 3 (table 3).
Overall, 3924 (2.10%) and 4428 (2.20%) patients received
ventilator support at admission in 2005 and 2006, respectively
(p=0.045, x
2 test). A total of 10 294 (5.51%) patients with CAP
received ventilator support at admission or during hospitalisa-
tion in 2005 and 12 106 (6.00%) in 2006 (p,0.001, x
2 test).
Mortality
Overall in-hospital mortality was 13.72% (95% CI 13.57% to
13.88%, n=25 622) in 2005 and 14.44% (95% CI 14.29% to
14.60%, n=29 132) in 2006 (p,0.001, x
2 test). Mortality varied
within hospitals from 0% to 40% and from 0% to 35% in 2005
and 2006, respectively.
In patients older than 40 years, mortality increased with age
(fig 4). There was no statistically significant difference in
mortality between men and women (overall RR=1.01; 95% CI
0.99 to 1.02.
Patients admitted from nursing homes had a statistically
significantly higher mortality (2005, 10 169/30 601, 24.94%;
2006, 11 674/33 943, 25.59%) compared with patients from
other provenances (2005, 15 453/130 468, 10.59%; 2006,
17 458/138 640, 11.18%) (RR=2.32; 95% CI 2.29 to 2.36).
Accordingly, chronically bedridden patients had a high mortal-
ity of 30.37% (30 745/101 249; RR=3.63; 95% CI 3.58 to 3.69).
On the other hand, excluding patients from nursing homes and
those who were chronically bedridden reduced the overall
mortality to 7.60% (19 842/261 038).
Mortality and comorbidities
In patients with defined comorbidities, the highest mortality
was observed in patients with malignant diseases (28.20% for
patients with tumours other than bronchial tumours, 25.21%
for patients with bronchial tumours). Pulmonary comorbidities
excluding COPD and dementia were also associated with a high
mortality of 24.45% and 22.36%, respectively, whereas patients
with COPD had a remarkably lower mortality of 10.12%
(table 4).
In 2005, non-survivors died at day day 5 (median, IQR 9 days)
after hospital admission, in 2006 at day 6 (median, IQR
10 days), respectively. However, most patients died within the
first days after hospitalisation (fig 5A). This pattern of mortality
was consistently present throughout CRB-65 scores, even in the
lowest CRB-65 class (fig 5B).
Of those patients who died during hospital stay, only 15.74%
(8618/54 754) had received ventilatory support at admission or
during hospitalisation (2005, 15.47% (3964/25 622); 2006,
15.98% (4654/29 132)). On the other hand, of those who
received ventilator support, 38.47% (8618/22 400) died (2005,
38.51% (3964/10 294); 2006, 38.44% (4654/12 106)). The
proportion of mechanically ventilated patients increased stea-
dily with age until the seventh age decade to 31.44%, but
decreased to 23.05% and 4.21% in the eighth and ninth decade,
respectively.
The proportions of mortality according to the three factors
associated with highest mortality cross-referenced with each
other are listed in table 5. These increased with every additional
factor from 25.29% to 42.79%.
Performance of CRB-65 severity score
The CRB-65 severity score predicted death in a three-class
pattern, with overall mortality of 2.40% in CRB-65 RC 1,
13.43% in CRB-65 RC 2 and 34.39% in CRB-65 RC 3 (table 6).
The length of hospital stay (was associated with the severity
of pneumonia (mean length of stay 9.45 vs 12.39 vs 14.50 days
(SD: 7.82, 8.47, 10.69) for RC 1–3, respectively, excluding
deaths).
DISCUSSION
The main results of the present analysis of this German
nationwide quality performance data on hospitalised patients
with CAP are the following:
Table 2 Patient comorbidity
Comorbidity
2005 2006 Total
n (% of 2005
population)
n (% of 2006
population)
n (% of overall
population)
Cardiac comorbidity 36 380 (19.49) 38 307 (18.99) 74 687 (19.23)
CNS disorders 25 660 (13.74) 27 763 (13.76) 53 423 (13.75)
Pulmonary diseases
(other than COPD)
23 506 (12.59) 27 171 (13.47) 50 677 (13.05)
Diabetes mellitus 22 189 (11.89) 23 991 (11.89) 46 180 (11.89)
COPD 17 247 (9.24) 19 314 (9.57) 36 561 (9.41)
Renal diseases 15 536 (8.32) 18 034 (8.94) 33 570 (8.64)
Dementia 11 037 (5.91) 12 129 (6.01) 23 166 (5.96)
Malignancy (other
than bronchial)
5805 (3.11) 6852 (3.40) 12 657 (3.26)
Lung cancer 2645 (1.42) 3427 (1.70) 6072 (1.56)
Liver diseases 2921 (1.56) 2948 (1.46) 5869 (1.51)
Total 100 381 (53.77) 109 616 (54.34) 209 997 (54.07)
Listed are the 10 most frequently recorded comorbidities.
Comorbidity as defined was present in 209 997 patients (54.07%). Some patients had
more than one comorbidity. Of patients with at least one comorbidity, 36 604
(17.43%) died.
CNS, central nervous system; COPD, chronic obstructive pulmonary disease.
Table 3 Pneumonia severity at admission according to the CRB-65 score
CRB-65 risk class 2005, n (%) 2006, n (%) Total, n (%)
1 (CRB-65=0) 30 285 (16.22) 33 982 (16.85) 64 267 (16.55)
2 (CRB-65=1, 2) 127 652 (68.38) 150 238 (74.48) 277 890 (71.55)
3 (CRB-65=3, 4) 28 754 (15.40) 17 495 (8.67) 46 249 (11.91)
Total patients with valid data (n) 186 691 201 715 388 406
The CRB-65 risk score is based on four parameters: C, mental confusion; R, respiratory rate >30/min; B, systolic blood pressure ,90 mm Hg or diastolic blood pressure
(60 mmHg; 65, age >65 years.
One point is assigned in the case of the presence of each parameter, adding up to a minimum of zero and a maximum of four points. The CRB-65 risk score classification is then
calculated as follows: CRB-65, 0 points equivalent to risk class 1; CRB-65, 1 or 2 points equivalent to risk class 2; CRB-65, 3 or 4 points or mechanical ventilation at admission
equivalent to risk class 3.
Respiratory infection
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related and increased with every decade until the eighth
decade.
c Mortality was higher than reported in previous studies of
selected patients.
c The first days of admission were associated with the highest
mortality, and this was consistently true throughout all
CRB-65 risk classes.
c The CRB-65 score accurately predicted death in a three-class
pattern.
c Only a minority of patients who died had received
mechanical ventilation during hospitalisation, hinting at a
limitation of treatment escalation for debilitated patients.
Previous epidemiological studies have reported a total
incidence of pneumonia including outpatient and inpatient
cases of about 1.6–12.0 per 1000 inhabitants and year.
12–14 In a
population-based study from a region of Barcelona, Spain, an
incidence of 1.62 was found.
12 Similar studies from Kuopio in
Finland and from Elche in Spain found a higher incidence of 11.6
per 1000 inhabitants and year and 12 per 10000 person-years,
respectively.
13 14 In a 1-year study of adult hospitalised CAP in
patients residing in two counties in Ohio, USA, the overall
incidence was 2.67 per 1000 inhabitants and year.
15 This latter
figure fits perfectly with the incidence found in our database.
We also could confirm the higher incidence of CAP in males.
In line with previous epidemiological data, the incidence of
CAP was strongly age related. Moreover, a very high number of
patients resided in nursing homes (22%) and were chronically
bedridden (26%). The highest incidence was reached in the very
old (80 years and older). Although these numbers are lower
than those reported in a recent large American study reaching
18.3 per 1000 population >65 years,
6 the estimated additional
future healthcare burden is impressive. Given the expected
increase in the elderly population in Germany (60 years and
older) up to 2050,
11 another 30 000–60 000 CAP cases will
require hospitalisation per year. Similar numbers are to be
expected in other ageing European and North American
countries.
16 17 Any future estimation of the healthcare burden
of CAP will have to realise that CAP essentially is mainly a
condition of the elderly.
Most surveys including patients with hospitalised CAP
reported a mortality of (10%.
5–7 12 17–19 In this analysis,
mortality was considerably higher. It seems reasonable to
assume that this difference can be explained mainly by the
exclusion of many high-risk patients in most clinical studies.
Accordingly, mortality in our analysis for patients admitted
from nursing homes was similar to the figures provided for
healthcare-related pneumonia (HCAP) in two recent studies
(19.8% vs 10%
20 and 24.6 vs 9.1%
21 as compared with 24.94% vs
11.18% in our study).
When looking at the time of death in non-survivors, there
was a striking excess risk of death in the first 7 days, with the
highest proportions during the first day after admission. This is
in line with a previous report in patients aged >65 years,
6 and
fits well with many studies indicating that the rapid initiation
of appropriate antimicrobial treatment is crucial for the
outcome.
22 23 Moreover, this trend was consistently evident
throughout all CRB-65 risk classes, implying that even patients
at lowest risk for lethal outcome are at their relatively highest
risk mainly within the first days after admission. Interestingly,
Figure 4 Distribution of in-hospital
death proportions of patients hospitalised
with community-acquired pneumonia
according to age classes (total population
in 2005 and 2006).






Malignancy (other than bronchial) 27.65 28.66 28.20
Lung cancer 25.07 25.33 25.21
Pulmonary diseases (other than COPD) 24.03 24.82 24.45
Dementia 21.93 22.76 22.36
Renal diseases 20.20 21.30 20.79
CNS disorders 19.27 19.54 19.41
Cardiac comorbidity 17.06 17.63 17.35
Diabetes mellitus 13.41 13.88 13.66
Liver diseases 12.26 13.60 12.93
COPD 9.85 10.37 10.12
Total 17.08 17.75 17.43
No comorbidity 12.50 13.35 12.95
Listed are the 10 most frequently recorded comorbidities.
Comorbidity as defined was present in 209 997 patients. Of these, 36 604 (17.43%)
died.
CNS, central nervous system; COPD, chronic obstructive pulmonary disease.
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deaths over time is the same for the subgroup managed
aggressively.
6
All studies assessing severity assessment scores have unan-
imously reported a substantial number of patients hospitalised
despite a low risk of death according to the score evaluated.
24–26
Although we do not have any information on the reasons for
hospitalisation of a large proportion of patients at low risk
according to CRB-65 severity assessment in the database
underlying this analysis (16–17%), the finding of an increased
risk of early death across all CRB-65 classes supports the clinical
notion that increased clinical attention is mandatory at least
during the first 2 days after admission.
Figure 5 (A) Crude number of deaths
during hospitalisation, stratified for CRB-
65 (C, mental confusion; R, respiratory
rate >30/min; B, systolic blood pressure
,90 mm Hg or diastolic blood pressure
(60 mm Hg; 65, age >65 years)
scores. Data refer to the whole population
in 2005 and 2006. Day 0 was not
calculated because it is not a complete
day. (B) Cumulative proportion of deaths,
stratified for CRB-65 scores. Note that the
highest mortality is observed during the
first days in all risk classes, even in the
lowest (CRB-65=0). Day 0 was not
calculated because it is not a complete
day.
Table 5 Proportion of mortality in patients with factors associated with
the highest mortality: admission from nursing home, bedridden status
and mechanical (non-invasive and invasive) ventilation













348 (42.08) 453 (43.35) 801 (42.79)
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Thorax 2009;64:1062–1069. doi:10.1136/thx.2008.109785 1067European authors were able to show that simple scores such
as the CURB, CURB-65 or CRB-65 score are at least not inferior
to the more complex PSI (pneumonia severity index) score.
26–28
Our data show that the simple CRB-65 score which is based
exclusively on three clinical signs and age predicts death from
CAP in a three-class pattern. The results are comparable with
those of the PSI score that predicts death in the range of 0.1–3%
in risk classes I–III, 8–13% in class IV and 29–31% in class V.
5
Although the database underlying this analysis does not allow a
comparison of CRB-65 and PSI in the same patients, the
performance of CRB-65 presented here adds strong evidence to
the usefulness of this score in the assessment of pneumonia
severity in real life and emphasises the preference for this simple
score as recently advocated.
29
An intriguing finding was the low number of patients who
died having previously received ventilatory support. Although
there are no nationwide recognised standard criteria for
ventilatory support, it can be regarded as a surrogate parameter
for intensive or at least intermediate care. The low proportion of
ventilated patients may therefore hint at a considerable number
of patients in whom a decision against ICU admission was
made. This view is supported by the decreasing proportions of
mechanical ventilation in the eighth and ninth age decade. Our
findings are in contrast to American data reporting admission to
ICU in 22.4% of cases aged >65 years and mechanical
ventilation in 7.2%.
6
The current guidelines on the management of adult CAP do
not mention the issue of care for patients with CAP as a
terminal event.
1–4 This is true despite a traditional notion of
CAP as ‘‘the old man’s friend’’, and despite some recent data
reporting a high frequency of ‘‘do not resuscitate’’ (DNR) orders
(22%) in patients with hospitalised CAP.
30 The ignorance
regarding CAP frequently representing a terminal disease no
longer seems acceptable. In selected chronically debilitated
patients it may be more appropriate for them to receive
treatment under the special considerations of terminal care.
However, such considerations must not rely exclusively on
decisions to withhold antimicrobial treatment
31 or on DNR
orders,
30 but there should be awareness of a range of potentially
applicable restrictions.
It might be argued that the population studied may have
included an uncertain proportion of patients with HCAP with
specific aetiological and microbial resistance patterns bearing an
excess mortality beyond age and nursing home pneumo-
nia.
20 21 32 In our view, the presence, incidence and characteristics
of HCAP directly reflect national and regional structures and
policies of healthcare in the chronically ill.
33 Thus, it seems
premature and potentially misleading to apply the concept of
HCAP in an indiscriminate way.
The main limitation of the present analysis and its underlying
database is the case definition of CAP. Since a case of CAP was
identified encoding pneumonia as the principal cause of hospital
admission, some cases may have been missed, mainly in the case
of CAP with severe sepsis or septic shock when the latter was
encoded asthe principal causeofhospital admission.Onthe other
hand, according to the imprecision of the ICD-10 code (IDC-10-
GM), it was not possible to exclude all cases with nosocomial
pneumonia. However, this would concern at most 4% of the
whole data set. Comparable previous large studies have also been
based on ICD codes.
67We were not able to validate the database
externally. However, biases from data validity are estimated to be
limited since the data evaluated here mainly included patient
characteristics and most simple clinical baseline data. This does
not fully apply to the reporting of comorbidity, and these data
must be regarded with caution. A nationwide study, on the other
hand, with the inclusion of all patients hospitalised with CAP—
that is, virtually no selection bias—is unique.
This analysis allows several conclusions. Hospitalised CAP is
mainly a condition of the elderly. Hospitalised CAP is a
condition with a considerable risk of early mortality after
admission, requiring rapid decisions about treatment settings
and modalities. It may be worth also giving special attention to
patients at low risk during this time frame. CRB-65 is a simple
and powerful tool for the assessment of CAP severity which
may be of help in routine clinical decision making. Obviously,
CAP is a frequent terminal event in chronic debilitated patients,
and a limitation of treatment escalation is frequently applied.
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ANSWER
From the question on page 1031
The scan showed synostoses of the C3/C4 and C5/C6/C7
vertebrae, consistent with Klippel-Feil syndrome. At C3/C4 the
disc-osteophyte complex was compressing the adjacent cord,
causing severe myelomalacia well above this level. Phrenic nerve
studies, including amplitudes and conduction velocities, were
normal bilaterally, reliably excluding lower motor neurone
pathology.
1 Bilateral diaphragmatic paralysis, demonstrated by
fluoroscopic monitoring during the sniff test, was therefore
secondary to interruption of the descending corticospinal
pathways supplying the phrenic nerve cell bodies, most of
which lie in the C4 neuromere adjacent to the C2/C3 disc. This
would account for his respiratory failure and we suspect that
the interruption was included in the extensive area of
myelomalacia above the cord lesion. This may initially have
been unilateral and asymptomatic, progressing only to respira-
tory failure when the right side became involved.
2 His ability to
compensate for this would have been decreased by his under-
lying chronic obstructive airways disease and high body mass
index.
Klippel-Feil syndrome is a congenital condition (incidence
1:40 000 births) of uncertain inheritance characterised by
synostosis of the cervical spine at one or multiple levels,
involving the vertebral bodies, facet joints and posterior arches.
The neck may be short and webbed with restricted movement
and the hairline low. Associated conditions include other
musculoskeletal deformities, deafness, heart defects and geni-
tourinary abnormalities.
3 Neurological complications secondary
to spinal cord and nerve root compression may occur in
childhood or later. The differential diagnosis of bilateral
diaphragmatic paralysis includes motor neurone disease, multi-
ple sclerosis, cervical myelopathy secondary to degenerative
spondylosis and spinal tumours.
45 The rapid onset of his
dyspnoea and absence of lower motor neurone pathology is
against motor neurone disease. His dyspnoea has subsequently
improved with conservative treatment.
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